BioAge’s Phase 2 trial to reverse immune aging

BioAge Labs - reversing aging

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Following compelling animal model data, BGE-175 to be used to treat COVID-19 in older patients by reversing immune aging.

Fresh from announcing a clinical trial targeting unexplained anaemia of aging, longevity biotech company BioAge Labs today announced the initiation of another Phase 2 trial, this time targeting COVID-19. The study will evaluate the efficacy and safety of BGE-175 to treat COVID-19 in patients aged 60 or older. Initial results are expected later this year.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE